5-乙基-(9ci)-2(1h)-嘧啶酮 | 64171-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-乙基-(9ci)-2(1h)-嘧啶酮
• 英文名称: 5-ethyl-1H-pyrimidin-2-one
• 英文别名: 5-Aethyl-1H-pyrimidin-2-on；5-Ethylpyrimidin-2(1H)-one；5-ethyl-1H-pyrimidin-2-one
• CAS: 64171-56-8
• 化学式: C₆H₈N₂O
• mdl: MFCD11848116
• 分子量: 124.142
• InChiKey: SYFKXBRRNSJBSJ-UHFFFAOYSA-N

物化性质

• 熔点：
  167 °C(Solv: carbon tetrachloride (56-23-5))
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933599090

反应信息

• 作为产物：
  描述：

  5-乙基-2(1H)-嘧啶硫酮 在 氯乙酸 作用下， 生成 5-乙基-(9ci)-2(1h)-嘧啶酮
  参考文献：
  名称：

  Determinants of Body Composition in Postmenopausal Women

  摘要：

  Background. Little is known about the effects of different levels of long-term physical activity on total body and regional fat and whether hormone replacement therapy interacts with physical activity level to affect body composition in postmenopausal women.Methods. We determined the associations between different levels of habitual physical activity, hormone replacement therapy (HRT), and total and regional body composition in postmenopausal women. Twenty sedentary, 20 active nonathletic, and 23 endurance-trained women (approximately half on HRT) had total and regional body composition assessed by dual-energy x-ray absorptiometry. The athletes and active nonathletic women had been active for the same number of years and the same number of hours per week.Results, The athletes and sedentary women weighed the same, but the active nonathletic groups on and not on HRT weighed 3-12 kg more (p < .05). Athletes had less trunk, arm, leg, and total body fat than sedentary and active nonathletic women (p < .05). Women on HRT tended to have lower total body (p = .07), but not regional, fat values. Linear regression analyses indicated that (V) over dot O-2 max in ml/kg/min was the major independent determinant of total and regional; body fat accounting for 52% to 70% of their variances. Athletes had greater caloric and carbohydrate intake than their less active peers, but all groups had similar protein, fat, saturated fat, monounsaturated fat, and polyunsaturated fat intakes.Conclusions. Intense training, but not low- to moderate-intensity physical activity, is associated with markedly lower levels of total and regional body fat in postmenopausal women. HRT has less of an effect on body composition than intense exercise training in postmenopausal women.

  DOI：

  10.1093/gerona/55.10.m607

文献信息

• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2019012001A1

  公开（公告）日：2019-01-17

  Compounds of the formula (I): (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.

  公式（I）的化合物：（I）其中取代基如权利要求1所定义，可用作杀虫剂，特别是作为杀真菌剂。
• SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE
  申请人：Bristol-Myers Squibb Company

  公开号：US20140011799A1

  公开（公告）日：2014-01-09

  The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了公式(I)的化合物：如规范中所定义的和包含任何此类新化合物的组合物。这些化合物是内皮细胞脂肪酶抑制剂，可用作药物。
• Methods and compositions for modulating splicing
  申请人：SKYHAWK THERAPEUTICS, INC.

  公开号：US11021708B2

  公开（公告）日：2021-06-01

  Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

  本文描述了可调节基因编码的 mRNA（如 pre-mRNA）剪接的小分子剪接调节剂化合物，以及使用小分子剪接调节剂化合物调节剪接和治疗疾病的方法。
• Methods for modulating splicing
  申请人：Skyhawk Therapeutics, Inc.

  公开号：US11129829B2

  公开（公告）日：2021-09-28

  Described herein are methods of use of small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.

  本文描述了小分子剪接调节剂化合物的使用方法，这些化合物可调节基因编码的 mRNA（如前 mRNA）的剪接，以及治疗与基因表达或基因编码的蛋白质活性相关的疾病和病症的方法。
• KRUSE R.; BREITMAIER E., CHEM. ZTG. <CZCA-A5>, 1977, 101, NO 6, 305-307
  作者：KRUSE R.、 BREITMAIER E.

  DOI：——

  日期：——